Chris Yu Healthcare News

This is selected healthcare news for Chris Yu, which is filed under People. There are 80 news items for this page. A press release filter page is also available for Chris Yu.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
10/30/2022 Josh Epstein, Kyle Rideout Team With Good Question Media for Dark Comedy ‘Knight's Camp’ (Exclusive) – Hollywood Reporter
... Rideout co-wrote the project with Rideout in the director's chair for a spring 2023 start. Producing are Dan Bekerman (Falling, The Witch) and Chris Yurkovich (Slash/Back) of Good Question Media, along with Epstein. Deanna Brigidi of 5th House Casting is casting. blogherads .defineSlot( ‚Aomedrec‚Ao, ‚Aogpt-article ...
thehoopsnews.com
9/28/2022 QualityStocksNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements
... operations as well as research and development, including its Class III medical device clinical trial,‚Au said AnPac Bio-Medical Science coCEO and cochair Dr. Chris Yu in the press release. ‚AuWe believe the investments signal continued confidence in the long-term and fundamental prospects of our company and its ...
blogspot.com
9/28/2022 MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements
... operations as well as research and development, including its Class III medical device clinical trial,‚Au said AnPac Bio-Medical Science coCEO and cochair Dr. Chris Yu in the press release. ‚AuWe believe the investments signal continued confidence in the long-term and fundamental prospects of our company and its ...
blogspot.com
9/27/2022 BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements
... operations as well as research and development, including its Class III medical device clinical trial,‚Au said AnPac Bio-Medical Science coCEO and cochair Dr. Chris Yu in the press release. ‚AuWe believe the investments signal continued confidence in the long-term and fundamental prospects of our company and its ...
inyoregister.com
9/27/2022 AnPac Bio and New Investor Group Sign Equity Investment
... to purchase 36.7 million of the Company's Class A shares. It is expected that the investment will be completed in late September 2022. Dr. Chris Yu, Co-Chairman of the board and Co-CEO of the Company, commented: ‚AuThis equity investment is important to the Company's operations as ...
Globe Newswire
9/27/2022 2022-09-26 | NDAQ:ANPC | Press Release | AnPac Bio-Medical Science Co. Ltd.
... purchase 36.7 million of the Company’s Class A shares. It is expected that the investment will be completed in late September 2022. Dr. Chris Yu, Co-Chairman of the board and Co-CEO of the Company, commented: ‚AuThis equity investment is important to the Company’s operations ...
stockhouse.com
9/27/2022 AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million
... to purchase 36.7 million of the Company's Class A shares. It is expected that the investment will be completed in late September 2022. Dr. Chris Yu, Co-Chairman of the board and Co-CEO of the Company, commented: ‚AuThis equity investment is important to the Company's operations as ...
Yahoo News
9/27/2022 AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million
... to purchase 36.7 million of the Company's Class A shares. It is expected that the investment will be completed in late September 2022. Dr. Chris Yu, Co-Chairman of the board and Co-CEO of the Company, commented: ‚AuThis equity investment is important to the Company's operations as ...
forextv.com
9/27/2022 ANPAC BIO MEDICAL SCIENCE CO LTD (ANPC) AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million
... to purchase 36.7 million of the Company's Class A shares. It is expected that the investment will be completed in late September 2022. Dr. Chris Yu, Co-Chairman of the board and Co-CEO of the Company, commented: ‚AuThis equity investment is important to the Company's operations as ...
researchpool.com
9/27/2022 AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million
... to purchase 36.7 million of the Company's Class A shares. It is expected that the investment will be completed in late September 2022. Dr. Chris Yu, Co-Chairman of the board and Co-CEO of the Company, commented: ‚AuThis equity investment is important to the Company's operations as ...
biotechwinners.com
9/27/2022 AnPac Bio Inks Deal for $3.7M Investment | 360Dx
... nine institutional investors agreed to buy 36.7 million Class A shares of the Shanghai-based cancer diagnostics firm at $0.10 per share. AnPac co-CEO Chris Yu said in an announcement that the investment would aid operations and research and development, including an ongoing Class III medical device trial needed ...
genomeweb.com
9/26/2022 AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million - Market Newsdesk
... to purchase 36.7 million of the Company's Class A shares. It is expected that the investment will be completed in late September 2022. Dr. Chris Yu, Co-Chairman of the board and Co-CEO of the Company, commented: ‚AuThis equity investment is important to the Company's operations as ...
marketnewsdesk.com
9/26/2022 AnPac Bio and New Investor Group Sign Equity Investment Totaling | ANPC Stock News
... Million to purchase 36.7 million of the Company's Class A shares. It is expected that the investment will be completed in late September 2022. Dr. Chris Yu, Co-Chairman of the board and Co-CEO of the Company, commented: "This equity investment is important to the Company's operations as well ...
stocktitan.net
9/12/2022 AnPac Bio Files CDA Device for Breakthrough Medical Device | UK NEWS TO DAY
... labs in China, development and validation work on CDA technology has also been conducted at AnPac Bio's CLIA/CAP accredited lab in Philadelphia. dr. Chris Yu, CEO and Chairman of AnPac Bio commented, ‚AuWe are thrilled with the CDA medical device's FDA filing for a groundbreaking medical device ...
chof360.com
6/1/2022 AnPac Bio Reports 49.1% Decrease in Net Loss in First
... to US$1.0 per share. The Company also issued 6,000,000 shares as reserve for potential convertible loans conversion in the first quarter of 2022. Dr. Chris Yu, Co-CEO and Co-Chairman of AnPac Bio commented: ‚AuWe are pleased with our overall performance in the first quarter of 2022. Our ...
Globe Newswire
4/11/2022 AnPac Bio-Medical Science appoints Dr. Aidong Chen as CEO and Chairman
... Bio-Medical Science (NASDAQ: [ANPC] ) has [appointed] Dr. Aidong Chen as its board director, CEO and Chairman of the board of Directors to succeed Dr. Chris Yu, company's founder, who resigned as board director, CEO and Chairman of the board. - As head of China operations of the company, Dr ...
Seeking Alpha
4/9/2022 AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive
... 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replaced Dr. Chris Yu, Company's founder, who resigned as board director, CEO and Chairman of the Board of the Company. As head of China operations of ...
Globe Newswire
4/5/2022 Juno Launches Comprehensive, Personalized Pediatric Care for Children in NYC
... Juno Pediatrics's first responsibility is to establish trust between the child's parents and the pediatric team, led by Dr. Danis Copenhaver and Dr. Chris Yun. Dr. Copenhaver believes it's important to listen to parents, communicate in an open and honest way, demonstrate caring, and provide the highest ...
marketersmedia.com
9/4/2021 Ellen "Paula" P. Yurk
March 18, 1947 - August 29, 2021 Ellen Paula Yurk (Deitrick), 74, passed away on August 29th, 2021, at McKee Medical Center in Loveland, Colorado. Ellen was born March 18, 1947, in Clark Fork, Idaho to Rex Wallace Deitrick and Ellen Fairbanks Deitrick. She married Howard Chris Yurk November 26, 1966 ...
longmontleader.com
11/25/2020 AnPac Bio-Medical Shares Rally Hard On Record Cancer Testing Volume
... on three areas: new product development, product commercialization including in the US, and revenue growth through sales, with an emphasis on execution and speed," CEO Chris Yu said in a statement. "We are optimistic about our company including commercialization in the U.S. and growth in 2021." At last check, AnPac ...
MSN
9/15/2020 AnPac Bio Receives Major Immunology Testing Contract
... related components, such as data around white blood cells, T cells and complements are already clinically validated and regulatory approved tests. AnPac Bio's CEO, Dr. Chris Yu, remarked, “This significant sales contract for our new immunology test ADME showed that our new product initiative and launch has received positive response ...
BioSpace
9/10/2020 AnPac Bio Reports First Six Months of 2020 Financial Results Nasdaq:ANPC
... approximately 180,500 samples as of June 30, 2020, including approximately 137,200 samples from commercial CDA-based tests and approximately 43,300 samples from research studies. Dr. Chris Yu, AnPac Bio's Chairman and CEO commented: “We have accomplished a number of critical milestones in the first half of the year, including its ...
Globe Newswire
9/10/2020 AnPac Bio Reports First Six Months of 2020 Financial Results
... approximately 180,500 samples as of June 30, 2020, including approximately 137,200 samples from commercial CDA-based tests and approximately 43,300 samples from research studies. Dr. Chris Yu, AnPac Bio's Chairman and CEO commented: “We have accomplished a number of critical milestones in the first half of the year, including its ...
BioSpace
9/4/2020 Diagnostic Methods Benefit from Rapidly Advancing Technologies
... cases, CDA values increased ahead of the onset of the cancer's recurrence, indicating that CDA technology could potentially be used as a recurrence monitor. Dr. Chris Yu , AnPac Bio's Chairman and CEO commented: "We are very pleased with the positive results from this multi-year, major clinical study. The results ...
PR Newswire
8/25/2020 Novel Cancer Treatments Arise as Scientists Search for Answers
... Pennsylvania. The AnPac Bio Philadelphia lab is dedicated to cancer differentiation analysis (CDA) liquid biopsy research as well as various other commercial diagnostic testing. Dr. Chris Yu , AnPac Bio's Chairman and CEO commented: 'We are very pleased about the CLIA registration for our laboratory in Philadelphia, Pennsylvania . We plan to ...
PR Newswire